Complement 3 Glomerulopathy Market Size was estimated to be USD 91.8 Million in 2020

The Complement 3 Glomerulopathy Market is set to grow substantially owing to the current treatment practices (mainly off-label treatments), launch of pipeline therapies, increase in funding, better awareness programmes and advent of novel biomarkers for better diagnosis.

The Complement 3 Glomerulopathy market report provides current treatment practices, emerging drugs, Complement 3 Glomerulopathy market share of the individual therapies, current and forecasted Complement 3 Glomerulopathy market Size from 2019 to 2032 segmented by seven major markets. The Report also covers current Complement 3 Glomerulopathy treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate the best of the opportunities and assesses the underlying potential of the Complement 3 Glomerulopathy market.

Key takeaways from the Complement 3 Glomerulopathy Market Research Report

• The market size of Complement 3 Glomerulopathy (C3G) in the seven major markets is estimated to be USD 91.8 Million in 2020.

• The total diagnosed prevalent population of Complement 3 Glomerulopathy (C3G) in the seven major markets was found to be 8,456 in 2020.

• The diagnosed prevalent cases of Complement 3 Glomerulopathy (C3G), in the United States, were found to be 4,112 in 2020.

• The leading Complement 3 Glomerulopathy Market Companies include Novartis Pharmaceuticals, pellis Pharmaceuticals, Omeros Corporation, ChemoCentryx, Amyndas Pharmaceuticals, and others.

• Promising Complement 3 Glomerulopathy Pipeline Therapies include Danicopan, Narsoplimab, Pegcetacoplan, LNP023, and others

For more insights into the Complement 3 Glomerulopathy Market Landscape, visit Complement 3 Glomerulopathy Market Therapeutics Landscape @ https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr
Recent Developmental Activities in the Complement 3 Glomerulopathy Treatment Landscape

• In December 2020, the company announced topline data from the Phase II ACCOLADE trial of avacopan for the treatment of patients with C3G. ChemoCentryx plans to discuss the evidence of clinical benefit of avacopan in C3G with the FDA in 2021 and also plans to discuss registration pathway with regulatory agencies in the US and EU. Currently, the drug is in the Phase II stage of clinical development for C3G.

• Pegcetacoplan (marketed as Empaveli) is approved in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria. Currently, the drug is being evaluated in phase II clinical developmental trial for patients with C3G and the company is planning to a phase III trial in second-half of 2021.

Complement 3 Glomerulopathy Epidemiology Segmentation in the 7MM

• Total Complement 3 Glomerulopathy Diagnosed Prevalent Population

• Complement 3 Glomerulopathy Type-specific Diagnosed Prevalent Population

• Complement 3 Glomerulopathy Age-specific Diagnosed Prevalent Population

To know more information of the Complement 3 Glomerulopathy Epidemiology Segmentation of the report, click here for Complement 3 Glomerulopathy Epidemiology Insights @ https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Complement 3 Glomerulopathy Marketed Drugs

• Iptacopan (LNP023): Novartis Pharmaceuticals
Novartis Pharmaceuticals is developing LNP023, which is an oral small-molecule inhibitor of complement factor B (FB) with potential immunomodulatory activity. Upon administration, FB inhibitor LNP023 binds to FB and prevents the formation of the alternative pathway (AP) C3-convertase (C3bBb). This limits the cleavage of C3 to the active fragment C3b and may prevent C3b-mediated extravascular hemolysis in certain complement-driven disorders such as C3G, paroxysmal nocturnal hemoglobinuria (PNH), etc. Currently, the drug is in phase III stage of clinical development for C3G with data read-out expected in 2023. In addition, Novartis is planning to file the drug in 2023 so that it can enter the market in near future, thereby meeting the demands of the patients

• Pegcetacoplan (APL-2): Apellis Pharmaceuticals
Apellis' Pegcetacoplan (APL-2) is an investigational, targeted C3 inhibitor designed to regulate excessive complement activation, which can lead to the onset and progression of many serious diseases. The company believes that this approach can regulate uncontrolled or excessive complement activation that occurs in several debilitating diseases, including those within hematology, ophthalmology, and nephrology. As per the company's research, the drug has the potential to be a best-in-class and first-in-class treatment that may address the limitations of existing treatment options or provide a treatment option where today there is none. Pegcetacoplan (marketed as Empaveli) is approved in the United States for the treatment of adults with paroxysmal nocturnal hemoglobinuria. Currently, the drug is being evaluated in phase II clinical developmental trial for patients with C3G and the company is planning to a phase III trial in second-half of 2021.

• Narsoplimab (OMS721): Omeros Corporation
Narsoplimab is a human monoclonal antibody targeting mannan-binding lectin-associated serine protease-2 (MASP-2), the effector enzyme of the lectin pathway of the complement system. This novel, proprietary drug is designed to prevent complement-mediated inflammation and endothelial damage while leaving intact the respective functions of the other pathways of innate immunity. The drug has completed a phase II trial for C3G. In addition to potential intravenous administration, Omeros plans to commercialize OMS721 for one or more therapeutic indications as a subcutaneous injection and is also developing small-molecule inhibitors of MASP-2. Based on requests from treating physicians, the company has established a compassionate-use program for OMS721, which is active in both the US and Europe

• Avacopan: ChemoCentryx
Avacopan (formerly known as CCX168) is an orally administered small molecule that is a selective inhibitor of the complement C5a receptor C5aR1. By precisely blocking the receptor (the C5aR) for the proinflammatory complement system fragment, C5a on destructive inflammatory cells such as blood neutrophils, avacopan arrests the ability of those cells to do damage in response to C5a activation, which is known to be the driver of inflammation. Moreover, avacopan's selective inhibition of only the C5aR1 leaves the beneficial C5a l pathway through the C5L2 receptor functioning normally. In December 2020, the company announced topline data from the Phase II ACCOLADE trial of avacopan for the treatment of patients with C3G. ChemoCentryx plans to discuss the evidence of clinical benefit of avacopan in C3G with the FDA in 2021 and also plans to discuss registration pathway with regulatory agencies in the US and EU. Currently, the drug is in the Phase II stage of clinical development for C3G.

Complement 3 Glomerulopathy Market Outlook
According to the National Kidney Foundation (NKF), C3G stands for complement 3 glomerulopathy. The "C3" refers to a blood protein that plays a key role in normal immunity and in the development of this disease whereas the "G" is for glomerulopathy, meaning damage to the glomeruli in the kidney. In addition, C3G includes dense deposit disease (DDD) and C3 glomerulonephritis (C3GN), which represent the two different patterns of damage and inflammation in the glomeruli. In other words, the damage and inflammation in the kidney tissue in DDD look different from that in C3GN when seen under a microscope.

Browse More Related Reports of the Complement 3 Glomerulopathy Market Research Reports, click here for Complement 3 Glomerulopathy Market Forecast @ https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Scope of the Complement 3 Glomerulopathy Market Report

• Coverage- 7MM

• Complement 3 Glomerulopathy Companies- Novartis Pharmaceuticals, pellis Pharmaceuticals, Omeros Corporation, ChemoCentryx, Amyndas Pharmaceuticals, and others.

• Complement 3 Glomerulopathy Pipeline Therapies- Danicopan, Narsoplimab, Pegcetacoplan, LNP023, and others.

• Complement 3 Glomerulopathy Market Dynamics: Complement 3 Glomerulopathy Market Drivers and Barriers

• Complement 3 Glomerulopathy Market Access and Reimbursement, Unmet Needs, Future Perspective

Read the Full Research Report of the Complement 3 Glomerulopathy Market Forecast Report, click here for Complement 3 Glomerulopathy Market Drivers and Barriers @ https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

Table of Content
1. Key Insights
2. Executive Summary of Complement 3 Glomerulopathy (C3G)
3. Competitive Intelligence Analysis for Complement 3 Glomerulopathy (C3G)
4. Complement 3 Glomerulopathy (C3G): Market Overview at a Glance
5. Complement 3 Glomerulopathy (C3G): Disease Background and Overview
6. Patient Journey
7. Complement 3 Glomerulopathy (C3G) Epidemiology and Patient Population
8. Treatment Algorithm, Current Treatment, and Medical Practices
9. Complement 3 Glomerulopathy (C3G) Unmet Needs
10. Key Endpoints of Complement 3 Glomerulopathy (C3G) Treatment
11. Complement 3 Glomerulopathy (C3G) Marketed Products
12. Complement 3 Glomerulopathy (C3G) Emerging Therapies
13. Complement 3 Glomerulopathy (C3G): Seven Major Market Analysis
14. Attribute analysis
15. 7MM: Complement 3 Glomerulopathy Market Outlook
16. Access and Reimbursement Overview of Complement 3 Glomerulopathy (C3G)
17. KOL Views
18. Complement 3 Glomerulopathy Market Drivers
19. Complement 3 Glomerulopathy Market Barriers
20. Appendix
21. DelveInsight Capabilities
22. Disclaimer
23. About DelveInsight

Consult with our Business Expert @ Complement 3 Glomerulopathy Market Landscape- https://www.delveinsight.com/sample-request/complement-3-glomerulopathy-c3g-market?utm_source=openpr&utm_medium=pressrelease&utm_campaign=ypr

About Us

DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.

Contact Us

Yash Bhardwaj

info@delveinsight.com

This release was published on openPR.